Autonomous targeting of infectious superspreaders using engineered transmissible therapies

PLoS Computational Biology

Volumn 7, Issue 3, 2011, Pages

  Metzger, Vincent T ^a   Lloyd Smith, James O ^b,c   Weinberger, Leor S ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITAL STORAGE; GENE THERAPY; PATHOGENS; POPULATION STATISTICS; VACCINES;

DISEASE SPREAD; DISEASE TREATMENT; DISINHIBITION; FIELD DATA; HIV/AIDS; INFECTIOUS DISEASE; LIVE ATTENUATED VACCINES; MULTISCALE MODELING; PATHOGEN RESISTANCE; SUB-SAHARAN AFRICA;

DISEASE CONTROL;

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; MOLECULAR THERAPY AGENT; THERAPEUTIC INTERFERING PARTICLE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GENETIC ENGINEERING; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INFECTION CONTROL; MATHEMATICAL MODEL; PREDICTION; RISK ASSESSMENT; TRANSMISSIBLE GENE THERAPY; VIRAL GENE THERAPY; VIRUS CARRIER; VIRUS LOAD; VIRUS RESISTANCE; VIRUS VIRULENCE; ANTIVIRAL RESISTANCE; CLINICAL TRIAL (TOPIC); GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MOLECULAR EVOLUTION; MUTATION; PREVALENCE; PROTEIN ENGINEERING; STATISTICAL MODEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENE THERAPY; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; MUTATION; PHARMACEUTICAL PREPARATIONS; PREVALENCE; PROTEIN ENGINEERING;

EID: 79953671625     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002015     Document Type: Article

References (49)

1. Hethcote HW, Yorke JA, (1984) Gonorrhea transmission dynamics and control. Berlin; New York Springer-Verlag. ix pp. 105 p.
2. Anderson RM, May RM, (1991) Infectious diseases of humans: dynamics and control. Oxford; New York Oxford University Press. viii.
3. Woolhouse ME, Dye C, Etard JF, Smith T, Charlwood JD, et al. (1997) Heterogeneities in the transmission of infectious agents: implications for the design of control programs. Proc Natl Acad Sci U S A 94: 338-342.
4. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM, (2005) Superspreading and the effect of individual variation on disease emergence. Nature 438: 355-359.
5. Pareto V, (1971) Manual of political economy. New York A. M. Kelley. xii pp. 504 p.
6. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, et al. (2009) Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 136: 1609-1617.
7. Grassly NC, Fraser C, Garnett GP, (2005) Host immunity and synchronized epidemics of syphilis across the United States. Nature 433: 417-421.
8. Woodhouse DE, Rothenberg RB, Potterat JJ, Darrow WW, Muth SQ, et al. (1994) Mapping a social network of heterosexuals at high risk for HIV infection. AIDS 8: 1331-1336.
9. May RM, Anderson RM, (1987) Transmission dynamics of HIV infection. Nature 326: 137-142.
10. Woolhouse ME, (1998) Patterns in parasite epidemiology: the peak shift. Parasitol Today 14: 428-434.
11. Sars Investigation Team from DMERI (2005) Strategies adopted and lessons learnt during the severe acute respiratory syndrome crisis in Singapore. Rev Med Virol 15: 57-70.
12. Baggaley RF, Garnett GP, Ferguson NM, (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3: e124.
13. Kahn JG, (1996) The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? Am J Public Health 86: 1709-1712.
14. Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, et al. (2005) The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. J Acquir Immune Defic Syndr 38: 202-207.
15. Holland JJ, (1990) Generation and replication of defective viral genomes. In: Fields BN, Knipe DM, editors. Fields Virology. 2nd ed. New York Raven Press pp. 77-99.
16. Klimatcheva E, Planelles V, Day SL, Fulreader F, Renda MJ, et al. (2001) Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol Ther 3: 928-939.
17. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.
18. An DS, Morizono K, Li QX, Mao SH, Lu S, et al. (1999) An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol 73: 7671-7677.
19. Weinberger LS, Schaffer DV, Arkin AP, (2003) Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol 77: 10028-10036.
20. Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC, (2006) Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 311: 236-238.
21. Fine PE, Carneiro IA, (1999) Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 150: 1001-1021.
22. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV, (2005) Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122: 169-182.
23. Chen J, Nikolaitchik O, Singh J, Wright A, Bencsics CE, et al. (2009) High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc Natl Acad Sci U S A 106: 13535-13540.
24. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
25. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP, (2007) Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 104: 17441-17446.
26. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, et al. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
27. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
28. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, et al. (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368: 531-536.
29. Garnett GP, Baggaley RF, (2009) Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 373: 9-11.
30. Fox MP, Rosen S, (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 15 (Suppl 1): 1-15.
31. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
32. Rosen S, Sanne I, Collier A, Simon JL, (2005) Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med 2: e303.
33. Baggaley RF, Griffin JT, Chapman R, Hollingsworth TD, Nagot N, et al. (2009) Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS 23: 1005-1013.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
35. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
36. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5: e1000274.
37. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, et al. (2002) Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol 76: 11953-11959.
38. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, et al. (2001) Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 15: 369-378.
39. Blower SM, Gershengorn HB, Grant RM, (2000) A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287: 650-654.
40. Barouch DH, (2008) Challenges in the development of an HIV-1 vaccine. Nature 455: 613-619.
41. Kirkwood TB, Bangham CR, (1994) Cycles, chaos, and evolution in virus cultures: a model of defective interfering particles. Proc Natl Acad Sci U S A 91: 8685-8689.
42. Endy D, Yin J, (2000) Toward antiviral strategies that resist viral escape. Antimicrob Agents Chemother 44: 1097-1099.
43. Read AF, Lynch PA, Thomas MB, (2009) How to make evolution-proof insecticides for malaria control. PLoS Biol 7: e1000058.
44. Temin HM, (1993) Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc Natl Acad Sci U S A 90: 6900-6903.
45. Davis BM, Humeau L, Dropulic B, (2004) In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther 9: 160-172.
46. Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, et al. (2010) HIV Sequence Variation Associated With env Antisense Adoptive T-cell Therapy in the hNSG Mouse Model. Mol Ther 18: 803-811.
47. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ, (2007) New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 15: 1910-1916.
48. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, et al. (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270: 470-475.
49. Blower SM, McLean AR, (1994) Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 265: 1451-1454.